Business Description
Aelis Farma SA
ISIN : FR0014007ZB4
Compare
Compare
Traded in other countries / regions
AELIS.France69O.Germany IPO Date
2022-02-18Description
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.01 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.31 | |||||
| Debt-to-EBITDA | -0.88 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 8.22 | |||||
| Beneish M-Score | -0.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -22.4 | |||||
| 3-Year FCF Growth Rate | -56.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.32 | |||||
| 9-Day RSI | 45.47 | |||||
| 14-Day RSI | 44.83 | |||||
| 6-1 Month Momentum % | -3.35 | |||||
| 12-1 Month Momentum % | -7.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.48 | |||||
| Quick Ratio | 2.47 | |||||
| Cash Ratio | 2.02 | |||||
| Days Sales Outstanding | 57.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.2 | |||||
| Shareholder Yield % | -0.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -71.36 | |||||
| Net Margin % | -56.09 | |||||
| FCF Margin % | -144.1 | |||||
| ROE % | -30.41 | |||||
| ROA % | -15.33 | |||||
| ROIC % | -62.58 | |||||
| ROC (Joel Greenblatt) % | -567.01 | |||||
| ROCE % | -24.5 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 18.6 | |||||
| PB Ratio | 12.99 | |||||
| Price-to-Tangible-Book | 13.13 | |||||
| EV-to-EBIT | -31.36 | |||||
| EV-to-EBITDA | -33.66 | |||||
| EV-to-Revenue | 17.03 | |||||
| EV-to-FCF | -11.82 | |||||
| Price-to-Net-Current-Asset-Value | 14.61 | |||||
| Price-to-Net-Cash | 24.07 | |||||
| Earnings Yield (Greenblatt) % | -3.19 | |||||
| FCF Yield % | -7.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aelis Farma SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9.054 | ||
| EPS (TTM) (€) | -0.391 | ||
| Beta | 0 | ||
| Volatility % | 5.3 | ||
| 14-Day RSI | 44.83 | ||
| 14-Day ATR (€) | 0.078763 | ||
| 20-Day SMA (€) | 13.005 | ||
| 12-1 Month Momentum % | -7.8 | ||
| 52-Week Range (€) | 12.8 - 14.1 | ||
| Shares Outstanding (Mil) | 13.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aelis Farma SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aelis Farma SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aelis Farma SA Frequently Asked Questions
What is Aelis Farma SA(XPAR:AELIS)'s stock price today?
The current price of XPAR:AELIS is €13.00. The 52 week high of XPAR:AELIS is €14.10 and 52 week low is €12.80.
When is next earnings date of Aelis Farma SA(XPAR:AELIS)?
The next earnings date of Aelis Farma SA(XPAR:AELIS) is .
Does Aelis Farma SA(XPAR:AELIS) pay dividends? If so, how much?
Aelis Farma SA(XPAR:AELIS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers